Introduction
Chronic heart failure (CHF) remains a significant global health burden, necessitating the identification of accessible biomarkers for risk stratification. Insulin resistance is a critical factor in cardiovascular pathology, yet its direct measurement is often impractical in clinical settings. The triglyceride-glucose (TyG) index, derived from fasting triglycerides and glucose, has emerged as a cost-effective proxy. This article discusses a formal correction to a retrospective cohort study investigating the association between the TyG index and mortality in Chinese CHF patients.
Methodological Refinements
The original study (Cardiovasc Diabetol 22:171) was a retrospective analysis. The correction clarifies several key methodological aspects:
- Patient Selection: The study strictly adhered to the 2021 European Society for Cardiology (ESC) Guidelines. Crucially, patients with acute exacerbations of CHF (AE-CHF), typically characterized by a left ventricular ejection fraction (LVEF) ≤40%, were excluded to maintain a homogenous chronic population.
- Statistical Terminology: A correction was made regarding the division of the patient cohort. The authors clarified that the group was divided into tertiles rather than quartiles. Linear trends were subsequently evaluated using the median value within each tertile as a continuous variable.
- Subgroup Analysis: Updates were made to the exploratory data (Additional file 1: Table S5) to ensure accurate representation of the TyG index's association with primary outcomes across various demographics.
Key Findings and Biological Mechanisms
Despite these technical adjustments, the primary conclusion remains robust: a higher TyG index is an independent and significant predictor of mortality in patients with CHF ($P$ for trend < 0.001).
The updated analysis highlighted particularly strong correlations in patients with hypertension and non-ischemic etiologies. This suggests a potential link to Heart Failure with preserved Ejection Fraction (HFpEF), which is more prevalent in these subgroups. Furthermore, the authors integrated findings from Yang et al. (2021), suggesting that the TyG index may reflect underlying myocardial fibrosis. This structural damage, detectable via MRI-based extracellular volume fraction measurements, provides a plausible biological mechanism for the increased mortality risk associated with high TyG levels.
Conclusion
The corrections issued for this study reinforce the validity of the TyG index as a clinical tool. By refining the patient population and statistical reporting, the authors have strengthened the evidence that insulin resistance, as captured by the TyG index, is a critical determinant of long-term outcomes in chronic heart failure. Future prospective studies are warranted to determine if therapeutic interventions targeting the TyG index can directly improve survival rates.
Summary updated